"At Acuity Pharmaceuticals we faced many challenges back in 2003. Five years later, we can view our scientific and financial successes with the benefit of hindsight to seek the contributing factors to that success. BioAdvance was one of the first companies we presented our company to. We received quick feedback and then were involved in a thorough diligence process which gave us more input and encouragement. At that early juncture, BioAdvance decided to invest, yet it was far more than money that made the difference. The BioAdvance team provided contacts and an effective sounding board for our development during those formative years."

Dale Pfost
Former CEO
Acuity Pharmaceuticals
Philadelphia, PA

Newsroom >> BioAdvance and Regional News

Today’s Top Regional Life Sciences Stories from Business Wire

Study shows GE Healthcare’s VisipaqueTM Associated with Lower Incidence of Contrast-Induced Nephropathy and Cardiovascular Events in Patients with Chronic Kidney Disease Compared to Iopromide

PRINCETON, N.J.--(BUSINESS WIRE)--A first-ever 208-person study comparing the renal safety, occurrence of cardiovascular adverse events and diagnostic image quality of GE Healthcare’s isosmolar contrast media

Deborah Debuts New Cath Lab Technology

BROWNS MILLS, N.J.--(BUSINESS WIRE)--Deborah Heart and Lung Center has announced its successful debut of the new Impella LP 2.5 device. The Impella 2.5 is a minimally-invasive, catheter-based cardiac assist device.

dbMotion Receives Healthcare IT Summit “Innovation Award”

PITTSBURGH, Pa.--(BUSINESS WIRE)--dbMotion, a premier provider of healthcare information integration software that facilitates interoperability and health information exchange (HIE), today announced it has been named a

Incyte to Present at the 20th Annual Piper Jaffray Health Care Conference

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) announced today it will present at the 20th Annual Piper Jaffray Health Care Conference on Wednesday, December 3, 2008 at 11:00 a.m. (Eastern Time).

Coughlin Stoia Geller Rudman & Robbins LLP Files Class Action Suit against PharmaNet Development Group, Inc.

NEW YORK--(BUSINESS WIRE)--Coughlin Stoia Geller Rudman & Robbins LLP (“Coughlin Stoia”) (http://www.csgrr.com/cases/pharmanet/) today announced that a class action has been commenced in the United

Morphotek®, Inc. Receives Additional $1.6M in Funding from The U.S. Department of Defense to Develop Therapeutic Antibodies Against Microbial Bioweapons

EXTON, Pa.--(BUSINESS WIRE)--Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, announced today that the company has received notice of $1.6M in additional funding from the U.S. Department of

PharmaNet Development Group Announces Exchange Offer for Its Outstanding 2.25% Convertible Senior Notes Due 2024

PRINCETON, N.J.--(BUSINESS WIRE)--PharmaNet Development Group, Inc. (the “Company”) (NASDAQ: PDGI), announced that it intends to commence today an offer to exchange all of its outstanding $143,750,000

Dr. Etienne Gagnon Receives CIHR BIOTECanada/Schering-Plough Canada Fellowship for Innovative Cancer Research

OTTAWA--(BUSINESS WIRE)--BIOTECanada and Schering Plough Canada are proud to congratulate Dr. Etienne Gagnon of Harvard Medical School on winning this year’s Canadian Institutes for Health Research

ImClone Systems’ State-of-the-Art Manufacturing Facility Receives FDA Approval for Multi-Product Biologics Production

NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that it has received approval from

Teva Provides Update on Generic Pulmicort Respules® Launch

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announces that further to its press release dated November 19, 2008, the United States District Court for the District of New Jersey has

LOGIN

PASSWORD